HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization -January 16, 2024 at 07:02 am EST

NEW YORK and VIENNA, Austria, Jan. 16, 2024 -- HOOKIPA Pharma Inc. , a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the...

Related Keywords

Vienna ,Wien ,Austria ,United States ,Mark Winderlich ,Joern Aldag ,Michael Kaiser ,Nasdaq ,Pharma Inc ,University Heidelberg ,Bristol Myers Squibb ,Chief Development Officer ,Chief Executive Officer ,Executive Vice President ,Global Scientific ,Molecular Biomedicine ,Medical Biometry ,Malte Peters ,Senior Clinical Advisor ,Human Papillomavirus ,Private Securities Litigation Reform Act ,Markets ,